 This study is designed to determine the optimal dose of JVRS-100 and assess safety, tolerability and immunogenicity of Fluzone vaccine administered with JVRS-100 adjuvant at one of three dose levels compared to Fluzone vaccine administered alone, in 472 adults aged 65 years. 